What did Oppenheimer change about the AQST analyst rating on Feb 2, 2026?

Oppenheimer maintained an **Outperform** rating on AQST on February 2, 2026 and described the FDA Complete Response Letter as a clearing event. No new price target accompanied the update.

How did AQST shares react to the maintained Outperform rating?

Shares fell **3.42% ($0.15)** after the note, indicating short-term investor caution despite the maintained Outperform view from Oppenheimer and ongoing regulatory updates.

Does the Oppenheimer note include an AQST price target?

Oppenheimer did not publish a new AQST price target with the February 2, 2026 note. The firm kept its Outperform rating without updating target guidance.

How should investors interpret the AQST analyst rating going forward?

Use the maintained Outperform as a positive signal on regulatory risk reduction, but combine it with company fundamentals, FDA developments, and Meyka AI grade before acting. Ratings are one input among many.

Analyst Ratings

Oppenheimer Maintains Outperform on AQST Aquestive Therapeutics Feb 2026

ByDanny Kontos February 3, 2026February 3, 2026

Oppenheimer maintained an Outperform rating on AQST (Aquestive Therapeutics, Inc.) on February 2, 2026. This AQST analyst rating frames Oppenheimer’s view that the FDA Complete Response Letter is a potential clearing event for the company. The firm kept the rating despite short-term selling, with the stock down 3.42% ($0.15) after the call. Market cap stands at $406,859,288, and no new price target was published with the note. We use Meyka AI-powered market analysis to explain what this rating means for investors.